Adagene Inc. (ADAG) is gaining traction with its platform-driven approach to antibody-based cancer therapies. The company's recent clinical milestone and regulatory alignment signal progress in its lead program, muzastotug (ADG126), and position it as a stock to watch in the biotech space.
Phase 2 Trial Milestone
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com